1. Home
  2. IMMP vs POLE Comparison

IMMP vs POLE Comparison

Compare IMMP & POLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • POLE
  • Stock Information
  • Founded
  • IMMP 1987
  • POLE 2024
  • Country
  • IMMP Australia
  • POLE United States
  • Employees
  • IMMP N/A
  • POLE N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • POLE
  • Sector
  • IMMP Health Care
  • POLE
  • Exchange
  • IMMP Nasdaq
  • POLE NYSE
  • Market Cap
  • IMMP 304.0M
  • POLE 294.2M
  • IPO Year
  • IMMP N/A
  • POLE 2024
  • Fundamental
  • Price
  • IMMP $2.17
  • POLE $9.98
  • Analyst Decision
  • IMMP Buy
  • POLE
  • Analyst Count
  • IMMP 2
  • POLE 0
  • Target Price
  • IMMP $8.50
  • POLE N/A
  • AVG Volume (30 Days)
  • IMMP 147.6K
  • POLE 5.0K
  • Earning Date
  • IMMP 12-27-2024
  • POLE 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • POLE N/A
  • EPS Growth
  • IMMP N/A
  • POLE N/A
  • EPS
  • IMMP N/A
  • POLE N/A
  • Revenue
  • IMMP $2,563,302.00
  • POLE N/A
  • Revenue This Year
  • IMMP N/A
  • POLE N/A
  • Revenue Next Year
  • IMMP $10.84
  • POLE N/A
  • P/E Ratio
  • IMMP N/A
  • POLE N/A
  • Revenue Growth
  • IMMP 9.59
  • POLE N/A
  • 52 Week Low
  • IMMP $1.66
  • POLE $9.94
  • 52 Week High
  • IMMP $3.34
  • POLE $11.16
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 55.07
  • POLE N/A
  • Support Level
  • IMMP $2.00
  • POLE N/A
  • Resistance Level
  • IMMP $2.39
  • POLE N/A
  • Average True Range (ATR)
  • IMMP 0.13
  • POLE 0.00
  • MACD
  • IMMP 0.01
  • POLE 0.00
  • Stochastic Oscillator
  • IMMP 54.17
  • POLE 0.00

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

Share on Social Networks: